Physician profile
Guy T Bernstein
NPI 1639178551
$25,229.95
in general payments reported to CMS, 2019-2025
71 companies · $4,850 in 2025
The $4,850 reported for 2025 was more than what 90% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,943 · 2020: $1,652 · 2021: $2,704 · 2022: $2,182 · 2023: $8,564 · 2024: $3,334 · 2025: $4,850.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,851 · Consulting Fee: $7,668 · Travel and Lodging: $135 · Education: $72.85 · Entertainment: $20.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,851.42 |
| Consulting Fee | $7,667.66 |
| Travel and Lodging | $135.33 |
| Education | $72.85 |
| Entertainment | $20.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $7,361.72 | 2019-2025 | Erleada |
| Pfizer INC. | $2,278.77 | 2019-2025 | |
| Astellas Pharma US INC | $2,071.16 | 2019-2025 | Xtandi, Myrbetriq, Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $1,052.42 | 2019-2025 | |
| Axonics, INC. | $966.33 | 2020-2024 | Axonics, Bulkamid |
| Dendreon Pharmaceuticals LLC | $796.42 | 2019-2025 | Provenge |
| Abbvie INC. | $736.00 | 2019-2025 | Botox |
| Urovant Sciences INC | $669.84 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $651.77 | 2023-2025 | Gemtesa, Orgovyx |
| Medtronic, INC. | $540.90 | 2022-2025 | Interstim |
| Janssen Scientific Affairs, LLC | $521.34 | 2021-2025 | Erleada |
| Teleflex LLC | $517.50 | 2021-2025 | Urolift |
| Cepheid | $492.00 | 2020 | |
| Neotract INC. | $443.08 | 2019-2020 | |
| C. R. Bard, INC. & Subsidiaries | $342.24 | 2020-2021 |
Show all 70 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Guy Bernstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.